icahn-mssm.university-tour.com
Apr 9, 2025, 07:12
Icahn School of Medicine at Mount Sinai – Results from the “REVERSE-IT” trial
Icahn School of Medicine at Mount Sinai posted on LinkedIn:
“Results from the “REVERSE-IT” trial show that bentracimab, an investigational monoclonal antibody, can safely and effectively reverse potentially catastrophic bleeding complications linked to ticagrelor, a common drug used to treat patients with acute coronary syndromes, prior heart attack, stroke, and coronary artery disease. The results were presented at ACC25 by Study Chair, Deepak L. Bhatt.
“If approved by the Food and Drug Administration, bentracimab could be a new life-saving option for someone having life-threatening bleeding, such as a brain hemorrhage,” says Dr. Bhatt.
Video attached to the post.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 17:49
Apr 15, 2025, 17:41
Apr 15, 2025, 17:17
Apr 15, 2025, 17:01
Apr 15, 2025, 16:16
Apr 15, 2025, 15:50